Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $662,143.37 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Rick Winningham sold 2,741 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the transaction, the director directly owned 9,567 shares in the company, valued at approximately $2,311,100.19. The trade was a 22.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ traded up $0.15 during mid-day trading on Wednesday, reaching $237.56. 615,345 shares of the stock were exchanged, compared to its average volume of 991,333. The business has a fifty day moving average price of $204.80 and a 200 day moving average price of $181.71. The firm has a market capitalization of $14.90 billion, a PE ratio of -11,872.06, a PEG ratio of 0.43 and a beta of 0.27. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $243.32. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. Research analysts expect that Jazz Pharmaceuticals PLC will post 20.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its holdings in shares of Jazz Pharmaceuticals by 11.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after buying an additional 298,815 shares during the last quarter. Ruffer LLP acquired a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $2,425,000. Essex Investment Management Co. LLC acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter worth approximately $2,697,000. JPMorgan Chase & Co. lifted its holdings in Jazz Pharmaceuticals by 8.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock worth $246,092,000 after purchasing an additional 145,865 shares during the last quarter. Finally, Iron Triangle Partners LP acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter worth approximately $19,770,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Bank of America lifted their price target on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. TD Cowen lifted their price target on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Morgan Stanley reissued an “overweight” rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Barclays lifted their price target on Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $188.00 to $307.00 in a research note on Tuesday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $242.65.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.